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A B S T R A C T
Cardiac toxicity as a side effect of chemotherapeutic agents has been well reported in the literature.
Cardiac toxicity secondary to alemtuzumab has been reported, presenting as congestive heart failure and
arrhythmias. Here we report a case of acute myocardial dysfunction after administration of a test dose of
alemtuzumab. Our patient was a 66-year-old man with a history of small lymphocytic lymphoma/
chronic lymphocytic lymphoma who received a test dose of alemtuzumab. Twenty minutes post
administration, the patient developed nausea, vomiting, rigors, and tachycardia. Electrocardiography
(ECG) showed acute ST-segment elevations in contiguous leads V2–V6, I, and AVL with no associated
chest pain. Bedside echocardiogram showed akinesis of the anterior septum, apex, distal anterior wall,
and decreased left ventricular ejection fraction. Cardiac catheterization showed non-critical occlusive
disease and no intervention was undertaken. Post-catheterization ECG revealed resolution of ST segment
elevations, TWI in V4–V6, and prolongation of corrected QT. Repeat echocardiogram 10 days after the
event demonstrated no improvement in wall motion or ejection fraction. We discuss the possible
mechanisms causing ST-elevations and acute myocardial dysfunction after treatment with alemtuzu-
mab.
<Learning objective: Alemtuzumab can cause acute myocardial dysfunction after administration of a
test dose. Considering that this is a serious adverse effect, detailed cardiac evaluation and a high level of
caution are recommended before administration of alemtuzumab. While no clear etiology could be
identiﬁed for this side effect, excessive and acute cytokine release triggered by alemtuzumab
administration is a possible explanation. This could be potentially attenuated by using anti-interleukin-6
or tumor necrosis factor inhibitors.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The spectrum of cardiovascular adverse effects secondary to
cancer chemotherapy has expanded with the development of new
chemotherapeutics, which now includes multiple biologic agents
[1]. Cardiac toxicity of several chemotherapeutic agents including
anthracyclines (doxorubicin, daunorubicin), alkylators (cyclophos-
phamide, cisplatin), antimetabolites (5-ﬂuorouracil, capecitabine),* Corresponding author at: Department of Internal Medicine, Monteﬁore Medical
Center, 111 East 210th Street, Bronx, NY 10467, USA. Tel.: +1 8576362471.
E-mail addresses: sattaria@monteﬁore.org, shirin.attarian@gmail.com
(S. Attarian).
http://dx.doi.org/10.1016/j.jccase.2014.07.004
1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightand targeted agents (trastuzumab, bevacizumab) has been well
documented [2].
Alemtuzumab is a humanized monoclonal antibody that targets
the CD52 antigen, which is a glycoprotein present on the cell
membrane of most T- and B-lymphocytes. It was initially approved
by the US Food and Drug Administration for the treatment of
ﬂudarabine-refractory chronic lymphocytic leukemia. Currently, it
is utilized in the treatment of other diseases such as multiple
sclerosis, mycosis fungoides, and Sezary syndrome, and in some
conditioning regimens for bone marrow, kidney, and islet cell
transplantation [3–6]. The well-deﬁned adverse effects of alemtu-
zumab include headache, hypotension, rash, anemia, neutropenia,
fever, chills, and autoimmune thyroid disorders [5]. Notable
cardiotoxic side effects of alemtuzumab include congestive cardiac
failure [4], arrhythmias, and acute myocardial infarction [7].s reserved.
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We present a 66-year-old man with a ﬁve-year history of small
lymphocytic lymphoma/chronic lymphocytic lymphoma, who was
initially treated with rituximab and bendamustine. Treatment was
complicated with severe allergic reactions, prompting continua-
tion of treatment with the study drug CAL101 for 4 months.
Subsequently, he received 2 cycles of ﬂudarabine and cyclophos-
phamide before he was admitted to the hospital for progressive
dyspnea and fever. Due to progression of his disease, the decision
was made to switch therapy to alemtuzumab and the patient
received a 3 mg test dose.
Twenty minutes after administration of the test dose, the
patient developed diaphoresis, tachycardia, nausea, vomiting,
rigors, and chills. Due to persistent tachycardia, an electrocardio-
gram (ECG) was obtained, demonstrating ST segment elevations in
precordial (V3–V6) and limb leads I, and aVL (Fig. 1a). Despite these
changes the patient denied any chest pain. Bedside transthoracic
echocardiogram (TTE) showed akinesis of the anterior septum,
apex, distal anterior wall, and a moderately decreased left
ventricular ejection fraction with normal right ventricular size
and function. These echocardiogram ﬁndings were new compared
to the TTE that was performed 15 days prior to the event
demonstrating normal left ventricular size, wall motion, and
function. Troponin levels sent 1 h after drug administration were
within normal limits [troponin-T = 0.01 ng/mL (normal range
<0.011 ng/mL), creatine kinase (CK)-MB% = 8.29, CK-MB = 2.8 ng/
mL (normal range <3 ng/mL), and creatine phosphokinase
(CPK) = 34 U/L (normal range: 20–200 U/L)].
Considering the new ﬁndings on ECG and echocardiogram there
was concern for acute myocardial infarction. The patient was
emergently treated with aspirin, clopidogrel, and was started on a
continuous heparin infusion. Immediately thereafter, the patient
underwent cardiac catheterization (Fig. 2). Cardiac catheterization
revealed a patent left main artery, 30% occlusion of the mid-left
anterior descending, 70% occlusion of the D1, patent right coronary
artery, patent ramus, an ejection fraction of 45%, left ventricular end
diastolic pressure of 6 mmHg, and an akinetic apex. No therapeutic
intervention was performed during the catheterization.Fig. 1.
(a) Electrocardiogram (ECG) 20 min after administration of alemtuzumab show
ECG indicating resolution of ST segment elevations, T wave inversions in V4Post-catheterization the patient had a heart rate of 95 beats per
min. On physical examination a S4 gallop was noted at the left
sternal border and coarse crackles were heard bilaterally at the
bases. ECG revealed stabilization of the ST segments, T wave
inversion in V4–V6, a prolonged QT, and no pathologic Q waves
(Fig. 1b). Repeat echocardiography approximately 16 h after
initiation of alemtuzumab and post-catheterization corroborated
left ventricular dysfunction (ejection fraction: 45%) and akinesis of
the antero-septum, apex, and distal anterior wall. Cardiac markers
12 h after the event showed no signiﬁcant changes (CPK 34 ! 55 U/
L, CK-MB% 8.2% ! 7.4%, and troponin-T 0.01 ! 0.03 ng/mL).
A repeat echocardiogram 10 days after drug administration
showed no improvement in left ventricular function (Fig. 3).
Unfortunately, the patient died 16 days after the administration of
alemtuzumab due to progression of his disease and a follow-up
echocardiogram to assess reversibility of left ventricular dysfunc-
tion was not possible. Autopsy could not be obtained.
Discussion
Cardiac toxicity in the form of congestive cardiac failure and
arrhythmias has been previously documented after treatment with
alemtuzumab [1,4,8]. However, some studies report no evidence of
cardiac toxicity [9,10]. Therefore, a causal relationship between
alemtuzumab remains a subject of debate within the literature.
The initial differential diagnosis for our case was broad, including
myocardial stunning, Takotsubo syndrome [11], chemotherapy-
induced cardiomyopathy, coronary vasospasm, and myocardial
infarction with rapid thrombus dissolution due to heparin
administration. Coronary vasospasm and acute myocardial infarc-
tion were the least likely diagnoses given the lack of signiﬁcant
troponin elevation. Basquiera et al. [7] reported a patient who
developed non-ST segment elevation myocardial infarction
(NSTEMI) after a 3 mg IV test dose of alemtuzumab followed by
subcutaneous infusion of a 10 mg dose. After the second infusion,
the patient developed fevers, dyspnea, typical chest pain, and
hypotension. Subsequently the patient was diagnosed with non-ST
elevation myocardial infarction. The same symptoms recurred after
the fourth administration of 30 mg of alemtuzumab. Therefore, foring ST segment elevations in V3–V6 and leads I, and aVL. (b) Post-catheterization
–V6.
Fig. 2.
Cardiac catheterization showing non-critical occlusive disease. (A) Contrast left ventriculography during diastole. (B) Contrast left ventriculography during
systole demonstrating akinesis. (C) Left coronary artery: diffuse disease throughout left coronary with non-critical occlusion. (D) Right coronary artery. LAD, left
anterior descending artery; RCA, right coronary artery.
S. Attarian et al. / Journal of Cardiology Cases 10 (2014) 176–179178the last 6 doses of alemtuzumab, nitroglycerin patches were
preventively placed with no further episodes of chest pain. Damaj
et al. [8] reported a case of coronary vasospasm associated with
fever, chills, and severe chest pain after infusion of 10 mg of
alemtuzumab. As opposed to these reports, our patient experienced
systemic symptoms such as nausea, vomiting, diaphoresis, rigors,Fig. 3.
Echocardiogram post catheterization. Four-chambered apical view 16 h
after the initial event, ejection fraction = 45%, with antero-septum,
apex, and distal anterior wall.and chills, but never complained of chest pain. Furthermore, our
patient showed acute ST elevations on ECG and did not show a
signiﬁcant increase in cardiac markers.
Our case presentation is similar to takotsubo or apical ballooning
syndrome (ABS) [11], which could be induced by microvascular
coronary spasm or direct catecholamine-mediated myocardial
stunning [12]. ABS is deﬁned as: (1) transient hypokinesis, akinesis,
or dyskinesis in the left ventricular mid segments with or without
apical involvement; regional wall motion abnormalities that extend
beyond a single epicardial vascular distribution; and frequently, but
not always, a stressful trigger; (2) the absence of obstructive
coronary disease or angiographic evidence of acute plaque rupture;
(3) new ECG abnormalities (ST-segment elevation and/or T-wave
inversion) or modest elevation in cardiac troponin; and (4) the
absence of pheochromocytoma and myocarditis [11]. A few cases of
takotsubo cardiomyopathy developing after exposure to bevacizu-
mab (a vascular endothelial growth factor inhibitor) have been
reported [13]. In those cases, left ventricular function recovery was
observed at 15 and 21 days. Although our case is similar to ABS, the
patient did not fully ﬁt the modiﬁed Mayo Clinic criteria for
takotsubo as there was no increase in the level of troponin and
hypokinesis of the wall was still evident one week later.
The association between cardiac adverse events, alemtuzu-
mab, and T-cell malignancies may be explained by a cytokine-
release syndrome, which is caused by increased levels of serum
tumor necrosis factor (TNF), interferon, and interleukin-6 [4,7].
Alemtuzumab may trigger the T cells to secrete these cytokines,
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dysfunction without infarction (stunning of the myocardium)
[4,8]. This cytokine release-related mechanism could explain why
cardiac adverse effects of alemtuzumab have been reported
mainly in patients with T-cell malignancies. An alternative
mechanism for the myocardial damage caused by alemtuzumab
could be a direct toxicity to the cardiac myocytes. Although there
is no evidence that CD52 is expressed on cardiac myocytes, it can
bind to the T cells that inﬁltrate the myocardium and cause
myocyte dysfunction or electrical disturbances as an unwanted
secondary effect [14–16]. While the pathophysiology in our case
could be explained by any of the mentioned mechanisms, lack of
immunohistochemistry and other pathophysiologic data limits
the accurate understanding of the underlying mechanism.
In summary, we report a patient with the diagnosis of small
lymphocytic lymphoma/chronic lymphocytic lymphoma, who was
treated with a test dose of alemtuzumab and developed acute
myocardial dysfunction. While no clear etiology could be
identiﬁed, excessive and acute cytokine release triggered by
alemtuzumab administration is a possible explanation, which
could be potentially attenuated by using anti-IL-6 or TNF
inhibitors. Further investigation is warranted to understand the
mechanisms causing adverse effects of chemotherapeutic agents.
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